A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show
18F-FLT
NSCLC
PET
pemetrexed
thymidine kinase
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jul 2023
22 Jul 2023
Historique:
received:
25
04
2023
revised:
14
07
2023
accepted:
20
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Thymidylate synthase (TS) remains a major target for cancer therapy. TS inhibition elicits increases in DNA salvage pathway activity, detected as a transient compensatory "flare" in 3'-deoxy-3'-[ Twenty-one patients with advanced/metastatic non-small cell lung cancer (NSCLC) scheduled to receive palliative pemetrexed ± platinum-based chemotherapy underwent Nineteen patients had evaluable PET scans at both time points. A total of 32% (6/19) of patients showed The better radiological response and longer survival observed in patients with an
Identifiants
pubmed: 37509378
pii: cancers15143718
doi: 10.3390/cancers15143718
pmc: PMC10377924
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : UK Medical Research Council
ID : MR/N020782/1, MC_U120081322
Organisme : Imperial College NIHR Biomedical Research Centre award
ID : WSCC_P62585
Organisme : Imperial College Experimental Cancer Medicines award
ID : C1312/A25149
Organisme : Cancer Research UK National Cancer Imaging Translational Accelerator award
ID : C2536/A28680
Organisme : NIHR Clinician scientist award
ID : 09/009
Références
PLoS One. 2012;7(5):e37229
pubmed: 22615946
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Med Chem. 2021 Jun 24;64(12):8179-8193
pubmed: 34085825
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 5;820(1):121-30
pubmed: 15866500
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):951-961
pubmed: 29362858
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4276s-4280s
pubmed: 15217974
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Eur J Cancer. 2016 Mar;55:81-97
pubmed: 26820682
Cancer Res. 2008 May 15;68(10):3827-34
pubmed: 18483267
Oncogene. 2022 Jan;41(5):745-756
pubmed: 34845374
J Thorac Oncol. 2014 Oct;9(10):1568-72
pubmed: 25521401
PLoS One. 2013 May 24;8(5):e63705
pubmed: 23717468
Eur J Cancer. 1995;31A(5):754-60
pubmed: 7640050
Biomarkers. 2013 Feb;18(1):88-94
pubmed: 23116493
Cancer Res. 2006 Sep 1;66(17):8558-64
pubmed: 16951168
Clin Cancer Res. 2009 Nov 1;15(21):6649-57
pubmed: 19861447
Clin Cancer Res. 2002 Jan;8(1):103-9
pubmed: 11801545
Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1339-47
pubmed: 17333178
Biomark Med. 2018 Apr;12(4):403-413
pubmed: 29575921
Oncotarget. 2017 Apr 11;8(15):24213-24223
pubmed: 27655645
Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):389-95
pubmed: 18931838
Clin Cancer Res. 2022 Nov 1;28(21):4634-4641
pubmed: 35984704
Clin Ther. 2005 Sep;27(9):1343-82
pubmed: 16291410
Nat Commun. 2016 Mar 24;7:11040
pubmed: 27010513
Nat Rev Clin Oncol. 2014 May;11(5):282-98
pubmed: 24732946
Clin Cancer Res. 2021 Nov 15;27(22):6115-6123
pubmed: 34521624
Phys Med. 2020 Aug;76:194-201
pubmed: 32707483